JP Morgan Maintains Overweight on Septerna, Raises Price Target to $38

3/24/2026
Impact: 75
Healthcare

JP Morgan analyst Tessa Romero has maintained an Overweight rating on Septerna (NASDAQ: SEPN) and raised the price target from $34 to $38. This adjustment reflects a positive outlook on the company's performance.

AI summary, not financial advice

Share: